M&A / Deals Cardio biotech Kardigan binds off $400M upsized IPO BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 19, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Cardiovascular Read full story Post navigation Previous: GSK claims FDA okay for first oral carbapenem antibioticNext: Heart drug biotech Kardigan raises $400m in upscaled IPO Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
